AstraZeneca : AZN forecasts very strong growth in 2021 but will do even better!
>Q4 results: guidance that shows AZN’s acceleration - AstraZeneca fully achieved its 2020 target, yesterday reporting EPS growth of 18% at constant exchange rates. The company was aiming for growth in the “mid to high teens at CER”, i.e. 16-19%. 2021 should enable a further acceleration in momentum since the company is aiming for EPS of between $ 4.75 and $ 5.00, i.e. reported growth of 18-24% (barely aided by a slightly positive currency effect of 1-3%). An important...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.